Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group.

Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4. Review.

2.

Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.

Largent EA, Harkins K, van Dyck CH, Hachey S, Sankar P, Karlawish J.

PLoS One. 2020 Feb 13;15(2):e0229137. doi: 10.1371/journal.pone.0229137. eCollection 2020.

3.

Large Capacity Enhancement of Carbon Electrodes by Solution Processing for High Density Energy Storage.

Farquhar AK, Smith SR, Dyck CV, McCreery RL.

ACS Appl Mater Interfaces. 2020 Mar 4;12(9):10211-10223. doi: 10.1021/acsami.9b17420. Epub 2020 Feb 20.

PMID:
32040296
4.

PET imaging of mGluR5 in Alzheimer's disease.

Mecca AP, McDonald JW, Michalak HR, Godek TA, Harris JE, Pugh EA, Kemp EC, Chen MK, Salardini A, Nabulsi NB, Lim K, Huang Y, Carson RE, Strittmatter SM, van Dyck CH.

Alzheimers Res Ther. 2020 Jan 18;12(1):15. doi: 10.1186/s13195-020-0582-0.

5.

Classical complement cascade initiating C1q protein within neurons in the aged rhesus macaque dorsolateral prefrontal cortex.

Datta D, Leslie SN, Morozov YM, Duque A, Rakic P, van Dyck CH, Nairn AC, Arnsten AFT.

J Neuroinflammation. 2020 Jan 6;17(1):8. doi: 10.1186/s12974-019-1683-1.

6.

Statin Use and Risk of Cognitive Decline in the ADNI Cohort.

Kemp EC, Ebner MK, Ramanan S, Godek TA, Pugh EA, Bartlett HH, McDonald JW, Mecca MC, van Dyck CH, Mecca AP; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2019 Nov 11. pii: S1064-7481(19)30559-7. doi: 10.1016/j.jagp.2019.11.003. [Epub ahead of print]

PMID:
31806426
7.

Quantum Interference Enhanced Chemical Responsivity in Single-Molecule Dithienoborepin Junctions.

Baghernejad M, Van Dyck C, Bergfield J, Levine DR, Gubicza A, Tovar JD, Calame M, Broekmann P, Hong W.

Chemistry. 2019 Nov 27;25(66):15141-15146. doi: 10.1002/chem.201903315. Epub 2019 Nov 4.

PMID:
31529793
8.

A global picture of family medicine: the view from a WONCA Storybooth.

Cubaka VK, Dyck C, Dawe R, Alghalyini B, Whalen-Browne M, Cejas G, Gibson C.

BMC Fam Pract. 2019 Sep 12;20(1):129. doi: 10.1186/s12875-019-1017-5.

9.

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2050. [Epub ahead of print]

10.

Extent of conjugation in diazonium-derived layers in molecular junction devices determined by experiment and modelling.

Van Dyck C, Bergren AJ, Mukundan V, Fereiro JA, DiLabio GA.

Phys Chem Chem Phys. 2019 Aug 14;21(30):16762-16770. doi: 10.1039/c9cp03509e. Epub 2019 Jul 22.

PMID:
31328202
11.

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.

PMID:
30970186
12.

Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.

Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS.

Alzheimers Dement (Amst). 2019 Feb 22;11:180-190. doi: 10.1016/j.dadm.2018.12.008. eCollection 2019 Dec.

13.

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.

Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Brain. 2019 Apr 1;142(4):1063-1076. doi: 10.1093/brain/awz019.

14.

What are the family medicine faculty development needs of partners in low- and middle-income countries?

Redwood-Campbell L, Dyck C, Delleman B, McKee R.

Educ Prim Care. 2019 Jan;30(1):29-34. doi: 10.1080/14739879.2018.1532322. Epub 2018 Oct 30.

PMID:
30376442
15.

Effects of Normative Adjustments to the Montreal Cognitive Assessment.

Pugh EA, Kemp EC, van Dyck CH, Mecca AP, Sharp ES; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2018 Dec;26(12):1258-1267. doi: 10.1016/j.jagp.2018.09.009. Epub 2018 Sep 21.

16.

Exploring Age-Related Changes in Resting State Functional Connectivity of the Amygdala: From Young to Middle Adulthood.

Xiao T, Zhang S, Lee LE, Chao HH, van Dyck C, Li CR.

Front Aging Neurosci. 2018 Jul 16;10:209. doi: 10.3389/fnagi.2018.00209. eCollection 2018.

17.

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.

Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH.

JAMA Neurol. 2018 Oct 1;75(10):1215-1224. doi: 10.1001/jamaneurol.2018.1836.

18.

Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.

Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, Trentalange M, Hawkins KA, Sano M, Arnsten AFT, van Dyck CH.

Neurobiol Aging. 2018 Oct;70:117-124. doi: 10.1016/j.neurobiolaging.2018.05.033. Epub 2018 May 31.

19.

Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI Cohort.

Mecca AP, Michalak HR, McDonald JW, Kemp EC, Pugh EA, Becker ML, Mecca MC, van Dyck CH; The Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Dement Geriatr Cogn Disord. 2018;45(3-4):232-242. doi: 10.1159/000488671. Epub 2018 Jun 8.

20.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

21.

HOMO Level Pinning in Molecular Junctions: Joint Theoretical and Experimental Evidence.

Rodriguez-Gonzalez S, Xie Z, Galangau O, Selvanathan P, Norel L, Van Dyck C, Costuas K, Frisbie CD, Rigaut S, Cornil J.

J Phys Chem Lett. 2018 May 3;9(9):2394-2403. doi: 10.1021/acs.jpclett.8b00575. Epub 2018 Apr 25.

PMID:
29660279
22.

Bottom-up, Robust Graphene Ribbon Electronics in All-Carbon Molecular Junctions.

Supur M, Van Dyck C, Bergren AJ, McCreery RL.

ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6090-6095. doi: 10.1021/acsami.7b19305. Epub 2018 Feb 8.

PMID:
29400435
23.

The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.

Scherer RW, Drye L, Mintzer J, Lanctôt K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH; ADMET 2 Research Group.

Trials. 2018 Jan 18;19(1):46. doi: 10.1186/s13063-017-2406-5.

24.

The aged rhesus macaque manifests Braak stage III/IV Alzheimer's-like pathology.

Paspalas CD, Carlyle BC, Leslie S, Preuss TM, Crimins JL, Huttner AJ, van Dyck CH, Rosene DL, Nairn AC, Arnsten AFT.

Alzheimers Dement. 2018 May;14(5):680-691. doi: 10.1016/j.jalz.2017.11.005. Epub 2017 Dec 11.

25.

Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.

Mecca AP, Barcelos NM, Wang S, Brück A, Nabulsi N, Planeta-Wilson B, Nadelmann J, Benincasa AL, Ropchan J, Huang Y, Gelernter J, Van Ness PH, Carson RE, van Dyck CH.

Neurobiol Aging. 2018 Jan;61:207-214. doi: 10.1016/j.neurobiolaging.2017.09.027. Epub 2017 Oct 6.

26.

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.

van Dyck CH.

Biol Psychiatry. 2018 Feb 15;83(4):311-319. doi: 10.1016/j.biopsych.2017.08.010. Epub 2017 Aug 24. Review.

27.

Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study.

Brumberg J, Küsters S, Al-Momani E, Marotta G, Cosgrove KP, van Dyck CH, Herrmann K, Homola GA, Pezzoli G, Buck AK, Volkmann J, Samnick S, Isaias IU.

Ann Clin Transl Neurol. 2017 Aug 11;4(9):632-639. doi: 10.1002/acn3.438. eCollection 2017 Sep.

28.

Chain Length Dependence of the Dielectric Constant and Polarizability in Conjugated Organic Thin Films.

Van Dyck C, Marks TJ, Ratner MA.

ACS Nano. 2017 Jun 27;11(6):5970-5981. doi: 10.1021/acsnano.7b01807. Epub 2017 Jun 14.

PMID:
28575578
29.

A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

30.

Behind the wheel: What drives the effects of error handling?

Dimitrova NG, van Hooft EAJ, van Dyck C, Groenewegen P.

J Soc Psychol. 2017;157(6):658-672. doi: 10.1080/00224545.2016.1270891. Epub 2016 Dec 14.

PMID:
27967717
31.

Lessons learned in global family medicine education from a Besrour Centre capacity-building workshop.

Dyck C, Kvern B, Wu E, McKee R, Redwood-Campbell L.

Educ Prim Care. 2016 Sep;27(5):391-395. Epub 2016 Aug 12.

PMID:
27684110
32.

Crew resource management training in the intensive care unit. A multisite controlled before-after study.

Kemper PF, de Bruijne M, van Dyck C, So RL, Tangkau P, Wagner C.

BMJ Qual Saf. 2016 Aug;25(8):577-87. doi: 10.1136/bmjqs-2015-003994. Epub 2016 Feb 3.

PMID:
26843412
33.

Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study.

van Dyck CH, Sadowsky C, Le Prince Leterme G, Booth K, Peng Y, Marek K, Ketter N, Liu E, Wyman BT, Jackson N, Slomkowski M, Ryan JM.

J Prev Alzheimers Dis. 2016;3(2):75-84. doi: 10.14283/jpad.2016.91.

PMID:
29210443
34.

Comparing three methods of computerised cognitive training for older adults with subclinical cognitive decline.

Gooding AL, Choi J, Fiszdon JM, Wilkins K, Kirwin PD, van Dyck CH, Devanand D, Bell MD, Rivera Mindt M.

Neuropsychol Rehabil. 2016 Oct;26(5-6):810-21. doi: 10.1080/09602011.2015.1118389. Epub 2015 Dec 16.

PMID:
26674122
35.

Responses to professional identity threat: Identity management strategies in incident narratives of health care professionals.

van Os A, de Gilder D, van Dyck C, Groenewegen P.

J Health Organ Manag. 2015;29(7):1011-28. doi: 10.1108/JHOM-12-2013-0273.

PMID:
26556165
36.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM.

JAMA Neurol. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607.

37.

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2015 Oct 20;85(16):1383-91. doi: 10.1212/WNL.0000000000002035. Epub 2015 Sep 11.

38.

The effect of orofacial myofunctional treatment in children with anterior open bite and tongue dysfunction: a pilot study.

Van Dyck C, Dekeyser A, Vantricht E, Manders E, Goeleven A, Fieuws S, Willems G.

Eur J Orthod. 2016 Jun;38(3):227-34. doi: 10.1093/ejo/cjv044. Epub 2015 Jul 1.

39.

Harnessing Quantum Interference in Molecular Dielectric Materials.

Bergfield JP, Heitzer HM, Van Dyck C, Marks TJ, Ratner MA.

ACS Nano. 2015 Jun 23;9(6):6412-8. doi: 10.1021/acsnano.5b02042. Epub 2015 Jun 4.

PMID:
26014273
40.

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.

Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH.

Alzheimers Res Ther. 2015 Apr 14;7(1):35. doi: 10.1186/s13195-015-0119-0. eCollection 2015.

41.

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.

Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, van Dyck CH, Nygaard HB, Strittmatter SM.

Ann Neurol. 2015 Jun;77(6):953-71. doi: 10.1002/ana.24394. Epub 2015 Mar 21.

42.

Molecular rectifiers: a new design based on asymmetric anchoring moieties.

Van Dyck C, Ratner MA.

Nano Lett. 2015 Mar 11;15(3):1577-84. doi: 10.1021/nl504091v. Epub 2015 Feb 26.

PMID:
25706442
43.

Evaluation of aviation-based safety team training in a hospital in The Netherlands.

De Korne DF, Van Wijngaarden JD, Van Dyck C, Hiddema UF, Klazinga NS.

J Health Organ Manag. 2014;28(6):731-53.

PMID:
25420354
44.

Implementation of Crew Resource Management: A Qualitative Study in 3 Intensive Care Units.

Kemper PF, van Dyck C, Wagner C, de Bruijne M.

J Patient Saf. 2017 Dec;13(4):223-231. doi: 10.1097/PTS.0000000000000145.

45.

More explicit communication after classroom-based crew resource management training: results of a pragmatic trial.

Verbeek-van Noord I, de Bruijne MC, Twisk JW, van Dyck C, Wagner C.

J Eval Clin Pract. 2015 Feb;21(1):137-44. doi: 10.1111/jep.12261. Epub 2014 Oct 15.

PMID:
25314899
46.

Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease.

Isaias IU, Spiegel J, Brumberg J, Cosgrove KP, Marotta G, Oishi N, Higuchi T, Küsters S, Schiller M, Dillmann U, van Dyck CH, Buck A, Herrmann K, Schloegl S, Volkmann J, Lassmann M, Fassbender K, Lorenz R, Samnick S.

Front Aging Neurosci. 2014 Aug 14;6:213. doi: 10.3389/fnagi.2014.00213. eCollection 2014.

47.

Barriers and facilitators for taking action after classroom-based crew resource management training at three ICUs.

Kemper PE, van Dyck C, Wagner C, Wouda L, de Bruijne M.

Jt Comm J Qual Patient Saf. 2014 Jul;40(7):311-8.

PMID:
25130014
48.

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2014 Apr 29;82(17):1536-42. doi: 10.1212/WNL.0000000000000364. Epub 2014 Apr 2.

49.

Myoblast alignment on 2D wavy patterns: dependence on feature characteristics and cell-cell interaction.

Grigola MS, Dyck CL, Babacan DS, Joaquin DN, Hsia KJ.

Biotechnol Bioeng. 2014 Aug;111(8):1617-26. doi: 10.1002/bit.25219. Epub 2014 May 1.

PMID:
24643546
50.

Fyn kinase inhibition as a novel therapy for Alzheimer's disease.

Nygaard HB, van Dyck CH, Strittmatter SM.

Alzheimers Res Ther. 2014 Feb 5;6(1):8. doi: 10.1186/alzrt238. eCollection 2014. Review.

Supplemental Content

Support Center